Chinese vice commerce minister said Monday that Beijing would like the U.S. to cancel "inappropriate" actions against Chinese companies.China Economyread more
Sixteen Asia Pacific countries have been negotiating the Regional Comprehensive Economic Partnership since 2013, with India's reluctance to open up its markets a major...Asia Economyread more
The secretary of State said he was traveling to Saudi Arabia and the United Arab Emirates to make sure that the U.S. is "strategically aligned" with its allies.Politicsread more
Experts say Facebook's cryptocurrency project Libra has been a catalyst for the price of bitcoin going higher.Technologyread more
Goldman Sachs helped state firm 1MDB to raise $6.5 billion in 2012 and 2013, and collected higher-than-typical fees of $600 million for the deals.Financeread more
Value investing has become increasingly irrelevant thanks to central banks and technology, according to AB Bernstein.Investingread more
Indonesian Trade Minister Enggartiasto Lukita said all 16 countries negotiating a mega Asia-Pacific trade agreement should remain in the framework.World Economyread more
Stocks in Asia Pacific traded mixed on Monday afternoon, while oil prices continued to rise as tensions between the U.S. and Iran lingered after the latter shot down an...Asia Marketsread more
His comments come after a series of rapid escalations between Washington and Tehran.World Politicsread more
The U.S. is provoking Iran and growing risks of miscalculation could lead to a "world war," according to Malaysia's Prime Minister Mahathir Mohamad.World Politicsread more
Trump's comments come after he called off strikes against the Islamic Republic this week over concerns that a military response would kill scores of people.Politicsread more
Jan 28 (Reuters) - A federal judge overseeing lawsuits alleging Bayer AG's glyphosate-based Roundup weed killer causes cancer on Monday tentatively allowed pieces of controversial evidence that the company had hoped to exclude from upcoming trials.
U.S. District Judge Vince Chhabria during a hearing in San Francisco federal court called his decision "probably most disappointing for Monsanto," the Bayer unit that manufactures the world's most widely used herbicide.
The company denies allegations that glyphosate causes cancer and says decades of independent studies have shown the chemical to be safe for human use.
Chhabria on Monday said plaintiffs could introduce some evidence of Monsanto's alleged attempts to ghostwrite studies and influence the findings of scientists and regulators during the first phase of upcoming trials. He said documents which showed the company taking a position on the science or a study introduced during the first phase were "super relevant."
The company had hoped the judge would take a harder line on such evidence following a Jan. 3 order by Chhabria restricting evidence of corporate misconduct. At the time, that decision lifted Bayer's shares nearly 7 percent.
Monsanto had argued much of this evidence was a "sideshow" that would only distract jurors from the scientific evidence.
Plaintiffs' lawyers contended some evidence of corporate misconduct was inextricably linked to their scientific claims.
The judge appeared to agree with them, saying it was difficult to draw the line between scientific evidence and allegations of corporate misconduct, and questioned whether it would be fair for the jury to not hear about the company's alleged attempts to influence scientists.
The parties did agree that other internal documents, including emails of Monsanto employees discussing lobbying efforts, do not belong in the initial trial phase.
Under Chhabria's order, that evidence would be allowed only if glyphosate was found to have caused plaintiff Edwin Hardeman's cancer and the trial proceeded to a second phase to determine Bayer's liability.
The order applies to Hardeman's case, which is scheduled to go to trial on Feb. 25, and two other upcoming cases. There are some 620 Roundup cases before Chhabria, out of more than 9,300 nationwide.
Plaintiffs' lawyers believe corporate misconduct evidence was critical to a California state court jury's August decision to award $289 million in a similar case. The verdict sent Bayer shares tumbling at the time, though the award was later reduced to $78 million and is under appeal. (Reporting by Tina Bellon in New York; Editing by Anthony Lin and Bill Berkrot)